Free Trial
→ Elon Social Security shock? (From Altimetry) (Ad)

Immunic Q3 2023 Earnings Report

Immunic logo
$1.18 +0.13 (+12.38%)
As of 02/20/2025 04:00 PM Eastern
Earnings HistoryForecast

Immunic EPS Results

Actual EPS
-$0.51
Consensus EPS
-$0.55
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Immunic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immunic Announcement Details

Quarter
Q3 2023
Date
11/14/2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Full Screen Slide Deck
Powered by Quartr

Immunic Earnings Headlines

Immunic highlights IMU-856's potential as weight management therapy
February 20 at 10:02 AM | proactiveinvestors.com
Immunic announces IMU-856 demonstrated dose-dependent increase
February 20 at 8:44 AM | markets.businessinsider.com
Elon “obliterates” Bill Gates?
All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors have all turned to my business partner and I for our thoughts on the market. And with every investor in America wondering what Elon is going to do now that he's in Washington, this is what we tell them
February 21, 2025 | Altimetry (Ad)
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
February 20 at 7:30 AM | prnewswire.com
IMUX stock touches 52-week low at $0.92 amid market challenges
February 12, 2025 | msn.com
Analysts Set Immunic, Inc. (NASDAQ:IMUX) Price Target at $12.67
February 11, 2025 | americanbankingnews.com
See More Immunic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunic and other key companies, straight to your email.

About Immunic

Immunic (NASDAQ:IMUX), a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

View Immunic Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles